Charles River Laboratories International (NYSE:CRL) Hits New 1-Year High Following Earnings Beat

Charles River Laboratories International, Inc. (NYSE:CRL)’s share price hit a new 52-week high during mid-day trading on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $253.00 and last traded at $258.39, with a volume of 3023 shares trading hands. The stock had previously closed at $234.12.

The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.74 by $0.28. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $977.20 million. During the same period last year, the business earned $3.12 EPS. Charles River Laboratories International’s quarterly revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS.

Analysts Set New Price Targets

Several research firms have recently issued reports on CRL. Evercore reiterated an “outperform” rating and set a $220.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Mizuho raised their price objective on Charles River Laboratories International from $192.00 to $230.00 and gave the company a “neutral” rating in a research report on Monday, July 13th. Morgan Stanley lifted their price objective on Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Sanford C. Bernstein set a $250.00 target price on Charles River Laboratories International in a report on Wednesday, July 1st. Finally, CLSA downgraded Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target for the company. in a report on Monday, July 20th. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus target price of $220.75.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the sale, the director directly owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Los Angeles Capital Management LLC purchased a new stake in Charles River Laboratories International in the 4th quarter worth approximately $42,000. Sfam LLC purchased a new position in Charles River Laboratories International in the 4th quarter worth approximately $43,000. Activest Wealth Management boosted its stake in Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after purchasing an additional 218 shares during the period. Elyxium Wealth LLC purchased a new stake in Charles River Laboratories International during the 4th quarter valued at approximately $46,000. Finally, Geneos Wealth Management Inc. raised its position in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

The stock has a market cap of $12.45 billion, a PE ratio of -68.72, a P/E/G ratio of 2.57 and a beta of 1.38. The firm’s fifty day moving average price is $209.54 and its 200 day moving average price is $188.12. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.